
    
      This is a prospective, multi-center, randomized controlled, open-label, superiority study. A
      total of 220 subjects will be enrolled from 10 sites in China. All subjects enrolled will be
      randomly assigned to the test group (Dissolve AV group, n=110) and the control group (Armada
      35 group, n=110) with randomized allocation ratio of 1:1. Subjects in the test group and the
      control group will be treated with Peripheral scoring drug balloon or Balloon Dilatation
      catheter
    
  